155 related articles for article (PubMed ID: 33803354)
1. Combined De-Repression of Chemoresistance Associated Mitogen-Activated Protein Kinase 14 and Activating Transcription Factor 2 by Loss of microRNA-622 in Hepatocellular Carcinoma.
Fritz V; Malek L; Gaza A; Wormser L; Appel M; Kremer AE; Thasler WE; Siebler J; Neurath MF; Hellerbrand C; Bosserhoff AK; Dietrich P
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33803354
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-216a-3p promotes sorafenib sensitivity in hepatocellular carcinoma by downregulating MAPK14 expression.
Wan Z; Liu T; Wang L; Wang R; Zhang H
Aging (Albany NY); 2020 Sep; 12(18):18192-18208. PubMed ID: 33021963
[TBL] [Abstract][Full Text] [Related]
3. Silencing activating transcription factor 2 promotes the anticancer activity of sorafenib in hepatocellular carcinoma cells.
Luo L; Cai L; Luo L; Tang Z; Meng X
Mol Med Rep; 2018 Jun; 17(6):8053-8060. PubMed ID: 29693700
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of microRNA-143-5p is required for the promotion of odontoblasts differentiation of human dental pulp stem cells through the activation of the mitogen-activated protein kinases 14-dependent p38 mitogen-activated protein kinases signaling pathway.
Wang BL; Wang Z; Nan X; Zhang QC; Liu W
J Cell Physiol; 2019 Apr; 234(4):4840-4850. PubMed ID: 30362514
[TBL] [Abstract][Full Text] [Related]
5. Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance.
Dietrich P; Koch A; Fritz V; Hartmann A; Bosserhoff AK; Hellerbrand C
Gut; 2018 Jul; 67(7):1328-1341. PubMed ID: 29275358
[TBL] [Abstract][Full Text] [Related]
6. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
7. The Ras-ERK signaling pathway regulates acetylated activating transcription factor 2 via p300 in pancreatic cancer cells.
Li M; Song SW; Ge Y; Jin JY; Li XY; Tan XD
Ann Transl Med; 2020 Oct; 8(19):1234. PubMed ID: 33178766
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-451 regulates activating transcription factor 2 expression and inhibits liver cancer cell migration.
Lv G; Hu Z; Tie Y; Du J; Fu H; Gao X; Zheng X
Oncol Rep; 2014 Sep; 32(3):1021-8. PubMed ID: 24968707
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
[TBL] [Abstract][Full Text] [Related]
10. microRNA-93-5p promotes hepatocellular carcinoma progression via a microRNA-93-5p/MAP3K2/c-Jun positive feedback circuit.
Shi X; Liu TT; Yu XN; Balakrishnan A; Zhu HR; Guo HY; Zhang GC; Bilegsaikhan E; Sun JL; Song GQ; Weng SQ; Dong L; Ott M; Zhu JM; Shen XZ
Oncogene; 2020 Aug; 39(35):5768-5781. PubMed ID: 32719439
[TBL] [Abstract][Full Text] [Related]
11. A microRNA-7/growth arrest specific 6/TYRO3 axis regulates the growth and invasiveness of sorafenib-resistant cells in human hepatocellular carcinoma.
Kabir TD; Ganda C; Brown RM; Beveridge DJ; Richardson KL; Chaturvedi V; Candy P; Epis M; Wintle L; Kalinowski F; Kopp C; Stuart LM; Yeoh GC; George J; Leedman PJ
Hepatology; 2018 Jan; 67(1):216-231. PubMed ID: 28833396
[TBL] [Abstract][Full Text] [Related]
12. Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic "dual-hit" option.
Dietrich P; Freese K; Mahli A; Thasler WE; Hellerbrand C; Bosserhoff AK
Oncotarget; 2018 Jan; 9(3):3605-3618. PubMed ID: 29423069
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines.
Kim JS; Choi GH; Jung Y; Kim KM; Jang SJ; Yu ES; Lee HC
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1487-1501. PubMed ID: 29858683
[TBL] [Abstract][Full Text] [Related]
14. CircSETD3 (Hsa_circ_0000567) acts as a sponge for microRNA-421 inhibiting hepatocellular carcinoma growth.
Xu L; Feng X; Hao X; Wang P; Zhang Y; Zheng X; Li L; Ren S; Zhang M; Xu M
J Exp Clin Cancer Res; 2019 Feb; 38(1):98. PubMed ID: 30795787
[TBL] [Abstract][Full Text] [Related]
15. Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Is a Novel Prognostic Marker and Contributes to Sorafenib Resistance in Hepatocellular Carcinoma.
Dietrich P; Gaza A; Wormser L; Fritz V; Hellerbrand C; Bosserhoff AK
Neoplasia; 2019 Mar; 21(3):257-268. PubMed ID: 30685691
[TBL] [Abstract][Full Text] [Related]
16. Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis.
Frau M; Feo F; Pascale RM
J Hepatol; 2013 Oct; 59(4):830-41. PubMed ID: 23665184
[TBL] [Abstract][Full Text] [Related]
17. Growth factors can activate ATF2 via a two-step mechanism: phosphorylation of Thr71 through the Ras-MEK-ERK pathway and of Thr69 through RalGDS-Src-p38.
Ouwens DM; de Ruiter ND; van der Zon GC; Carter AP; Schouten J; van der Burgt C; Kooistra K; Bos JL; Maassen JA; van Dam H
EMBO J; 2002 Jul; 21(14):3782-93. PubMed ID: 12110590
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of MicroRNA-19b predicts good prognosis in patients with hepatocellular carcinoma presenting with vascular invasion or multifocal disease.
Hung CL; Yen CS; Tsai HW; Su YC; Yen CJ
BMC Cancer; 2015 Oct; 15():665. PubMed ID: 26453548
[TBL] [Abstract][Full Text] [Related]
20. Activation of extracellular signal-regulated kinase is associated with hepatocellular carcinoma with aggressive phenotypes.
Minagawa T; Yamazaki K; Masugi Y; Tsujikawa H; Ojima H; Hibi T; Abe Y; Yagi H; Kitago M; Shinoda M; Itano O; Kitagawa Y; Sakamoto M
Hepatol Res; 2020 Mar; 50(3):353-364. PubMed ID: 31702093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
